LIPOTEC USA, INC. – Trademark Portfolio
Entity Type: 03
LIPOTEC USA, INC. holds 20 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 20 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 3 Nice Classification classes. Currently, 17 trademarks are registered. Notable registered marks include ACTICEL, ACTIGEN, ACTISEA, ACTIFCOL, and ACTIFIRM. The owner is based in LEWISVILLE, TX.
1097 YATES STREET
LEWISVILLE, TX 75057
Showing of trademarks Trademarks
Trademark Classifications
LIPOTEC USA, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does LIPOTEC USA, INC. have?
LIPOTEC USA, INC. has 20 U.S. trademarks filed with the USPTO. Of these, 17 registered, 1 abandoned, 2 cancelled.
What trademark classes does LIPOTEC USA, INC. file in?
LIPOTEC USA, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are LIPOTEC USA, INC.'s most well-known trademarks?
LIPOTEC USA, INC.'s registered trademark portfolio includes well-known marks such as ACTICEL, ACTIGEN, ACTISEA, ACTIFCOL, and ACTIFIRM. These are among 17 currently registered trademarks in the portfolio.
What is LIPOTEC USA, INC.'s trademark registration success rate?
LIPOTEC USA, INC. has a 85% trademark registration rate, with 17 out of 20 resolved applications resulting in successful registration. Currently, 0 applications are pending review.